Sangamo Therapeutics Net Income 2006-2021 | SGMO

Sangamo Therapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Sangamo Therapeutics Annual Net Income
(Millions of US $)
2020 $-121
2019 $-95
2018 $-68
2017 $-55
2016 $-72
2015 $-41
2014 $-26
2013 $-27
2012 $-22
2011 $-36
2010 $-25
2009 $-19
2008 $-24
2007 $-21
2006 $-18
2005 $-13
Sangamo Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $-48
2021-06-30 $-47
2021-03-31 $-46
2020-12-31 $-41
2020-09-30 $-2
2020-06-30 $-36
2020-03-31 $-43
2019-12-31 $5
2019-09-30 $-27
2019-06-30 $-30
2019-03-31 $-42
2018-12-31 $-19
2018-09-30 $-13
2018-06-30 $-17
2018-03-31 $-20
2017-12-31 $-13
2017-09-30 $-12
2017-06-30 $-12
2017-03-31 $-17
2016-12-31 $-10
2016-09-30 $-19
2016-06-30 $-27
2016-03-31 $-16
2015-12-31 $-14
2015-09-30 $-9
2015-06-30 $-12
2015-03-31 $-5
2014-12-31 $-4
2014-09-30 $-8
2014-06-30 $-7
2014-03-31 $-8
2013-12-31 $-8
2013-09-30 $-6
2013-06-30 $-5
2013-03-31 $-7
2012-12-31 $-3
2012-09-30 $-6
2012-06-30 $-6
2012-03-31 $-7
2011-12-31 $-6
2011-09-30 $-10
2011-06-30 $-10
2011-03-31 $-10
2010-12-31 $-8
2010-09-30 $-9
2010-06-30 $-4
2010-03-31 $-4
2009-12-31 $-2
2009-09-30 $-5
2009-06-30 $-5
2009-03-31 $-7
2008-12-31 $-3
2008-09-30 $-6
2008-06-30 $-7
2008-03-31 $-8
2007-12-31 $-7
2007-09-30 $-4
2007-06-30 $-5
2007-03-31 $-5
2006-12-31 $-9
2006-09-30 $-3
2006-06-30 $-3
2006-03-31 $-3
2005-12-31 $-3
2005-09-30 $-4
2005-06-30 $-3
2005-03-31 $-4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.932B $0.118B
Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69